Mov Disord-New Marker: Sphingosine-1-phosphate can predict the progression of Parkinson’s disease

Parkinson's disease (PD) is a neurodegenerative disease with many potential mechanisms

In cell culture experiments, S1P protects dopaminergic neurons from cells induced by 1-methyl-4-phenyl-4-propionic acid (MPP) by activating S1P receptor 1 (S1PR1) signaling and enhancing mitochondrial biogenesis.

In addition to in vitro experiments, the S1P receptor modulator fingolimod reduced the aggregation of α-synapse, increased brain-derived neurotrophic factor (BDNF), weakened dopaminergic neurodegeneration, and reduced striae The decline in dopamine levels in the body ultimately reduced the dyskinesia in the PD mouse model induced by different drugs

While most studies have focused ontheir own immunity on the immunomodulatory effects of the disease, but S1P in cerebral vascular function also plays an important role

Although experimental studies in vitro and in vivo have shown that S1P has a neuroprotective effect in PD models, the relationship between serum S1P levels and PD and its phenotype has not been studied yet

They used liquid chromatography-tandem mass spectrometry (LC-MS/MS) to analyze the S1P concentration in the serum of 196 Parkinson's disease patients and 196 age- and gender-matched control groups

They found that compared with the control group, PD patients had lower S1P levels, 1.

In PD patients, lower S1P concentration is related to higher UPDRS III score and Hoehn and Yahr stages

In the follow-up cohort, in the sub-median group, the S1P concentration was related to the speed of the decline in exercise capacity (HR=4.

Original source: